Meeting report
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies
1 Kite Pharma Inc, Los Angeles, CA, USA
2 Galena Biopharma, Inc, Lake Oswego, OR, USA
3 Northwest Biotherapeutics, Bethesda, MD, USA
4 Aduro Biotech, Berkeley, CA, USA
5 Department of Medicine, Surgery and Immunology, UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, Pittsburgh, PA, USA
6 California Stem Cell, Irvine, CA, USA
7 Oxford BioMedica, Oxford, UK
8 Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
9 Department of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
10 Department of Transfusion Medicine; Infectious Disease and Immunogenetics Section, National Institutes of Health, Bethesda, MD, USA
11 Division of Medical Oncology, University of Washington, Seattle, WA, USA
12 Dendreon Corp, Seattle, WA, USA
13 Center for Medical Research, University of Tübingen, Tübingen, Germany
14 Advaxis Inc Genomics Institute of the Novartis Research Foundation, Princeton, NJ, USA
15 Immunotherapeutics Group, National Institutes of Health, Bethesda, MD, USA
16 Department of Immunology, University of Connecticut Health Center, Farmington, CT, USA
17 Arrowhead Publishers and Conferences, Minneapolis, MN, USA
18 Immatics Biotechnologies GmbH, Tübingen, Germany
19 Arrowhead Publishers and Conferences, Minneapolis, MN, USA
Journal of Translational Medicine 2012, 10:218 doi:10.1186/1479-5876-10-218
Published: 5 November 2012Abstract
While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.
